CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with a significant increase in full-year revenue due to a new GSK licensing agreement, a substantial upfront payment, and improved operating profit. The Q&A section indicates management's cautious optimism, and despite some vague responses, they reaffirm a strong cash position and financial runway. The strategic restructuring and workforce reduction pose some risks, but the overall sentiment is positive due to the financial improvements and strategic partnerships.
Key Financial Performance
Cash Position EUR481.7 million at the end of 2024, increased from EUR402.5 million at the end of 2023, primarily due to a EUR400 million upfront payment from GSK.
Revenue (Q4 2024) EUR14.5 million, decreased by EUR8.1 million compared to Q4 2023, driven by the recognition of one-time revenue events in the previous year.
Revenue (Full Year 2024) EUR535.2 million, increased by EUR481.4 million compared to 2023, primarily driven by the new licensing agreement with GSK.
Operating Loss (Q4 2024) EUR43.8 million, improved from an operating loss of EUR88 million in Q4 2023, due to reduced costs associated with the new licensing agreement.
Operating Profit (Full Year 2024) EUR177.7 million, compared to an operating loss of EUR274.2 million in 2023, driven by decreased cost of sales and strategic changes in R&D.
Financial Results (Q4 2024) EUR5.2 million, increased by EUR3.7 million compared to Q4 2023, due to improved financial performance.
Financial Results (Full Year 2024) EUR13.2 million, decreased by EUR1 million compared to 2023, primarily due to lower interest income on cash investments.
Pre-tax Loss (Q4 2024) EUR38.6 million, compared to a pre-tax loss in the same period of 2023.
Pre-tax Profit (Full Year 2024) EUR190.9 million, compared to pre-tax losses in the same period of 2023.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Oncology Pipeline: CureVac's oncology pipeline includes a Phase 1 study for glioblastoma, which has completed enrollment of Part B, and a new off-the-shelf precision immunotherapy for squamous non-small cell lung cancer that received IND clearance from the FDA.
Infectious Diseases Pipeline: CureVac has initiated a program for a prophylactic vaccine against uropathogenic E. coli bacteria, targeting urinary tract infections, with promising preclinical data.
Licensing Agreement with GSK: CureVac signed a licensing agreement with GSK valued up to EUR1.45 billion, which includes a EUR400 million upfront payment and potential milestone payments.
GSK Clinical Programs: GSK has initiated a combined Phase 1/2 study for a seasonal influenza and COVID-19 combination vaccine based on CureVac's mRNA technology.
Restructuring Plan: CureVac completed a strategic restructuring plan, reducing its workforce by approximately 30%, which is expected to decrease operating expenses by over 30% from 2025.
Cash Position: CureVac closed 2024 with a strong cash position of EUR482 million, providing a financial runway into 2028.
Focus on R&D: CureVac has refocused its strategy on technology innovation and R&D, streamlining operations to enhance efficiency and agility.
IP Portfolio: CureVac's split poly-A tail patent was upheld by the European Patent Office, reinforcing its position in mRNA technology.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Issues: CureVac is involved in ongoing litigation with Pfizer-BioNTech regarding intellectual property rights, which could impact their operations and financial stability.
Supply Chain Challenges: The company has terminated all remaining raw material commitments and closed contract manufacturing organization related arbitrations for their first-generation COVID-19 vaccine, ensuring no further related payments.
Economic Factors: CureVac's financial results were affected by a significant one-time payment of EUR400 million from a licensing agreement with GSK, which may not be repeated in future periods.
Competitive Pressures: CureVac faces competition in the mRNA vaccine space, particularly from established players like Pfizer-BioNTech, which could impact their market position and revenue.
Operational Risks: The company underwent a strategic restructuring, including a 30% workforce reduction, which may pose risks related to operational efficiency and employee morale.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Restructuring: CureVac undertook a strategic corporate restructuring, including a 30% workforce reduction, to enhance operational efficiency and focus on R&D priorities.
Licensing Agreement with GSK: A licensing agreement with GSK valued up to EUR1.45 billion was signed, providing significant capital and leveraging GSK's expertise in infectious diseases.
Pipeline Expansion: CureVac is advancing its pipeline in oncology and infectious diseases, with key programs in glioblastoma and squamous non-small cell lung cancer.
Intellectual Property Validation: The European Patent Office upheld the validity of CureVac's split poly-A tail patent, reinforcing its position in mRNA technology.
Cash Position: CureVac closed 2024 with a strong cash position of EUR482 million, providing a financial runway into 2028.
Revenue Expectations: CureVac anticipates a substantial decrease in operating expenses by over 30% from 2025 onwards, including a EUR25 million reduction in personnel costs.
Clinical Milestones: Key catalysts expected in 2025 include data from the glioblastoma study and the initiation of the squamous non-small cell lung cancer program.
Future IND Filings: CureVac plans to file an IND for its UPEC vaccine program in the second half of 2025, with Phase 1 clinical development expected to start in the first half of 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Upfront Payment from GSK: Received EUR400 million as a nonrefundable payment for granting licenses to GSK.
Milestone Payment from GSK: EUR10 million milestone payment invoiced in Q4 2024 for the initiation of a Phase 1 study.
Total Cash Position: Closed 2024 with a strong cash position of EUR482 million.
Expected Cash Runway: Reaffirmed expected financial runway into 2028.
Revenue Recognition: EUR80.4 million recognized as revenue from remaining contract liabilities.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the early signs of activity for the squamous program's antigens outside of the exome?
A:We have extensive validation assays for our antigens, looking at tumor expression, immune recognition, and tumor cell killing. Preclinical evidence shows strong immune responses and cancer regressions in animal models.
Q:Will the first patient dose in the second half of this year lead to a mid or second half '26 readout from the Phase 1?
A:We are cautious about sharing projections for data readouts due to the nature of first-in-human studies and the need for dose escalation.
Q:What is the regulatory path for the CVGBM asset?
A:We have not seen any negative impact from recent FDA changes. We plan to discuss Phase 2 after Phase 1 data shows meaningful clinical activity.
Q:What criteria will be used to make go/no-go decisions for GBM?
A:We expect to see an overall survival of 50 months or longer and an overall response rate of about 20% to proceed.
Q:How does the number of antigens affect anti-tumor activity?
A:Animal models do not allow us to investigate this directly, but we believe a diverse immune response is beneficial.
Q:What is included in the cash runway guidance into 2028?
A:The cash runway includes our core programs and clinical phases, but not all Phase 1 and Phase 2 costs are covered before potential cash out.
Q:What is the strategy for collaboration in oncology and infectious disease programs?
A:We focus on technology innovation and early development, aiming to partner for late-stage development.
Q:What are the timelines for the European Patent proceedings?
A:The next hearing is on May 13-15, and if validity is confirmed, the infringement court hearing is scheduled for July 1st.
Q:Can you provide details on the Genmab collaboration termination?
A:The collaboration was dormant and did not lead to progress, so it was mutually agreed to terminate.
Q:What are the criteria for moving to early-stage settings in the lung cancer program?
A:We need to see immune responses and clinical activity to justify moving to earlier stages.
Q:How do you expect R&D costs to progress through 2025?
A:We aim for efficiency and cost reduction while focusing on our pipeline programs.
Q:Can you discuss the mRNA integrity data shown on Slide 13?
A:The integrity is within regulatory specifications even after a year at room temperature.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the specific timeline for data readouts from the Phase 1 trial and the exact criteria for moving to early-stage settings in the lung cancer program. Their responses were vague about the cash runway details and the impact of the recent FDA changes on their programs.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
COVID vaccine
EPO
GSK program
IND
LNP system
Phase study
agreement GSK
antigen collaboration
cancer immunotherapy
cell lung
condition
degree Celsius
degree Fahrenheit
glioblastoma study
infringement
inhibitor
licensing agreement
loss EUR
lung cancer
milestone payment
oncology disease
outcome
patent form
patient cell
payment GSK
pembrolizumab
precision immunotherapy
program cell
program influenza
restructuring
study disease
tail patent
treatment
validity split
CVAC Transcript
CureVac N.V. (NASDAQ:CVAC) Q4 2024 Earnings Call Transcript
Positive4-12
The earnings call indicates a significant improvement in financial performance, with a shift from operating losses to profits, and strong revenue growth due to a new partnership with GSK. Despite a slight EPS miss, the cash position is strong, and the company is strategically focusing on oncology. The Q&A section reveals cautious optimism in clinical trials and regulatory interactions, with no major negative surprises. Overall, the financial health and strategic focus on partnerships suggest a positive market reaction.
CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript
Positive4-10
The earnings call highlights strong financial performance with a significant increase in full-year revenue due to a new GSK licensing agreement, a substantial upfront payment, and improved operating profit. The Q&A section indicates management's cautious optimism, and despite some vague responses, they reaffirm a strong cash position and financial runway. The strategic restructuring and workforce reduction pose some risks, but the overall sentiment is positive due to the financial improvements and strategic partnerships.
CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript
Positive11-12
The earnings call highlights a strong financial performance, primarily due to a €400 million upfront payment from GSK, resulting in a significant revenue increase and a transition to operating profit. While there are concerns about litigation and R&D investment risks, the overall sentiment is positive due to strong cash position and promising business updates. The Q&A section did not reveal major negative surprises, and the optimistic guidance on oncology and infectious diseases further supports a positive outlook. The stock price is likely to react positively in the short term.
CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript
Unknown4-24
The earnings call reveals mixed signals: a strong cash position and increased Q4 revenue, but a full-year revenue decline and increased operating loss. The Q&A highlights uncertainties in vaccine timelines and oncology trials. Despite efficiency gains, cost management challenges persist. No guidance was provided, which typically concerns investors. Without a market cap, a neutral prediction is prudent, balancing positive cash flow extensions and strategic risks.
CVAC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
